Gene methylation Vedolizumab Gene expression CARCINOGENESIS Colectomy Méthylation Patients experience Colorectal cancer Contraindication Dysbiosis Inflammatory Bowel Diseases IL23 Gènes Disease progression Biomarker Survival Resistance Endoscopic treatment Colorectal cancer Colibactin and lipids Inflammatory bowel disease Disability Helicobacter pylori Ustekinumab Thérapie ciblée Epigénétiques Inclusion Cell adhesion Effectiveness Inhibitor Tuberculosis Upper gastrointestinal tract Eradication Immune cells Safety Stricture Monitoring Kidney diseases Fecal microbiota MICROBIOTA PCR Maintenance therapy Screening Crohn's disease DNA methylation Résistance Epigenetics DNA METHYLATION Bacteria IL12 COLON-CANCER Dysbiose Over 80s Ulcerative colitis MORTALITY Intestinal crypts Venous thromboembolism 18 FDG-PET/CT Therapeutics Clinical guidelines Consensus Immunosuppressant Heart disease risk factors Disease Progression Original Article Clinical Tailored therapy Cost effectiveness Clinical trial Drug Genes Cancer Crohn’s disease RISK Colonic epithelial primary cells IBD Acceptability Anti-TNF Rituximab Methylation MARKER Neoadjuvant chemotherapy Microbiote Bactéries T1118 translocation Patient-reported outcome MALT Rituximab plus chlorambucil Small molecules Eligibility Microbiota Colon Alkylating agents Surgery Biologics Colon cancer HIV Algorithm Parvimonas micra Inflammatory bowel diseases Primary sclerosing cholangitis Anti-TNF agents